Meeting
2019 ASCO Annual Meeting
A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).
Authors
Julia Katharina Schwarze
Universitair Ziekenhuis Brussel, Brussels, Belgium
Julia Katharina Schwarze , Valerie Vandersleyen , Gil Awada , Yanina Jansen , Teofila Seremet , Bart Neyns
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02941744
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9585)
DOI
10.1200/JCO.2019.37.15_suppl.9585
Abstract #
9585
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2021 ASCO Annual Meeting
Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.
First Author: James Larkin
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Robert R. McWilliams